Blood pressure and coronary heart disease
Clinical Trial Service Unit and ICRF Cancer Studies Unit, Radcliffe Infirmary, Oxford OX2 6HE, UKThe Lancet (Impact Factor: 45.22). 09/1990; 336(8711):370-1. DOI: 10.1016/0140-6736(90)91908-S
[Show abstract] [Hide abstract]
- "Secondly, the multifactorial effect of the insulin resistance syndrome17. Thirdly, a delay of the full benefit of the antihypertensive treatment given is possible, given too short a follow up period of the trials.33 "
ABSTRACT: An account is given of recent literature regarding the major cardiovascular risk factors. It considers high blood pressure, high blood cholesterol, smoking, as well as insulin resistance and its metabolic consequences. The focus is on the current available evidence in terms of causal associations of these risk factors with the occurrence of cardiovascular disease, and the evidence of the benefits of risk factor lowering. The multiplicative effect of risk factors and their multifactorial role in the genesis of cardiovascular disease is now firmly established and will affect the mode of approach to preventive measures. The main preventive options currently available are twofold, a population-wide approach and a high risk approach. The suitability of primary health care as one of the main providers of preventive care is today widely acknowledged. The need for cardiovascular risk assessment to be multifactorial and made in terms of overall actual risk is of paramount importance. The implications of this overall issue for countries like those of the Middle East, where the prevalence of cardiovascular disease is on the rise, are of great concern.03/1995; 2(1):19-26.
- [Show abstract] [Hide abstract]
ABSTRACT: Numerous epidemiological studies have shown that blood pressure (BP) is positively related to cardiovascular morbidity and mortality. Although the relationship between BP and the incidence of morbid events is consistent and highly significant, it is difficult to predict the absolute risk. Several studies have shown that the organ damage associated with hypertension correlate to a greater degree with 24 h average BP than with clinic BP and the most of them evaluated left ventricular hypertrophy in these patients. To evaluate the correlation between left ventricular mass index (LVMi) and BP, BP variability, pulse pressure (PP), BP load and hyperbaric index (HBI). Ambulatory blood pressure monitoring (ABPM) was performed in 30 children with renal disease aged 12.7 +/- 5.5 years. Ten of them had normal renal function, 3 had renal transplant and 17 of them had end-stage renal disease and were on chronic haemodialysis. All of the patients were submitted to an echocardiographic evaluation and LVMi was calculated according to Penn convention. Ambulatory blood pressure monitoring was performed during the 24 h period and average values of systolic and diastolic BP were evaluated. As an index of variability of BP values we used standard deviation (SD) of mean. Evaluation of average BP values has some disadvantages--it does not take into account the peaks of blood pressure and the values are lower if the circadian rhythm of BP is preserved--for this reason BP load and HBI were evaluated as well. BP load represented the percentage of BPs exceeding the upper limits of normal and HBI the integrated area under the ambulatory BP curve. For the upper limits of normal was used 95th percentile from the multicenter study of German authors. There was no correlation between LVMi and evaluated parameters. The response of myocardium to chronic increase of the afterload is highly individual, and probably the role of genetics in this is very important. Echocardiography (LVMi) could not be used with certainty for the evaluation of ventricular mass.Srpski arhiv za celokupno lekarstvo 131(7-8):300-5. · 0.23 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.